The global investigational new drug (IND) CDMO market is experiencing robust growth as pharmaceutical innovation accelerates worldwide. The market, valued at USD 5.29 billion in 2024, is projected to surge to USD 10.34 billion by 2034, growing at a CAGR of 6.97% from 2025 to 2034. This growth is fueled by increasing drug development activities, AI-driven service platforms, and rising private and public investments in the pharmaceutical sector.
Contract Development and Manufacturing Organizations (CDMOs) play a critical role in helping pharmaceutical companies bring investigational new drugs (INDs) to market. With advanced technologies and global footprints, CDMOs offer end-to-end services, including preclinical development, clinical trial material manufacturing, and regulatory support.
Market Size (2024): USD 5.29 billion
Market Forecast (2034): USD 10.34 billion
CAGR (2025–2034): 6.97%
Leading Region: North America (44–48% market share in 2024)
Fastest Growing Region: Asia Pacific
Top Segment (2024): Small Molecules (45–50% share)
Emerging Segment: Advanced Therapies (highest forecast CAGR)
About: AGC Biologics is a global CDMO known for its biologics and cell therapy expertise.
Products: Biopharmaceuticals, plasmid DNA, viral vectors.
Market Cap: Approx. USD 1.2 billion.
About: Curia offers integrated drug discovery, development, and manufacturing solutions.
Products: APIs, biologics, drug product manufacturing.
Market Cap: Private (acquired by Carlyle Group in 2017).
About: A leading CDMO with a strong presence in China and the US, specializing in small molecule drugs.
Products: Process R&D, API production, formulation.
Market Cap: Approx. USD 5.1 billion.
About: Cambrex is a key player in small molecule drug development and manufacturing services.
Products: APIs, drug substances, finished dosage forms.
Market Cap: Private (acquired by Permira in 2019).
About: Catalent delivers advanced solutions in drug delivery technologies and development.
Products: Biologics, gene therapy, oral and inhalation delivery.
Market Cap: Approx. USD 8.5 billion.
About: CordenPharma specializes in APIs, excipients, and lipid nanoparticles for innovative drugs.
Products: Lipid synthesis, mRNA encapsulation, peptide APIs.
Market Cap: Private.
About: A division of Eurofins Scientific, providing comprehensive drug development services.
Products: API development, finished product manufacturing.
Market Cap: Parent company Eurofins Scientific: USD 13 billion.
About: Evotec offers integrated solutions from drug discovery to manufacturing.
Products: Biologics, small molecules, cell therapy services.
Market Cap: Approx. USD 5.3 billion.
About: A global CDMO with strong capabilities in biologics and advanced therapies.
Products: Viral vectors, monoclonal antibodies, cell culture systems.
Market Cap: Parent company Fujifilm Holdings: USD 25 billion.
About: Lonza is one of the largest CDMOs globally, serving the pharmaceutical and biotech industries.
Products: Biologics, cell & gene therapies, APIs.
Market Cap: Approx. USD 38 billion.
About: MedPharm specializes in topical and transdermal drug delivery solutions.
Products: Semi-solid and liquid formulations, dermatology drugs.
Market Cap: Private.
About: Patheon, under Thermo Fisher, provides integrated pharmaceutical development and manufacturing.
Products: APIs, drug products, packaging solutions.
Market Cap: Parent company Thermo Fisher: USD 215 billion.
About: PCI offers end-to-end solutions for drug development, including packaging and distribution.
Products: Clinical trial services, commercial manufacturing.
Market Cap: Private.
About: A part of Piramal Pharma, it offers end-to-end development and manufacturing services.
Products: APIs, drug products, injectable formulations.
Market Cap: Approx. USD 2 billion.
About: Quotient Sciences provides an integrated approach to speed up drug development timelines.
Products: Formulation development, clinical trial manufacturing.
Market Cap: Private.
AI Integration: Platforms enhanced with AI for efficient drug development workflows.
Collaborations: Increased partnerships between pharmaceutical companies and CDMOs.
Regional Expansion: Emerging markets like Asia Pacific driving demand.
Government Support: Rising investments in pharmaceutical infrastructure globally.
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
The market is projected to grow at a CAGR of 6.97% between 2025 and 2034.
North America leads with a 44–48% share as of 2024.
Key companies include Lonza, Catalent, Thermo Fisher (Patheon), AGC Biologics, and Fujifilm Diosynth.
Increased drug development, AI-driven services, and government investments are major growth drivers.
Advanced therapies are expected to register the highest CAGR during the forecast period.
Source : https://www.towardshealthcare.com/insights/investigational-new-drug-cdmo-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5866
🏥 Rapid Expansion of the Medical Device Sector Asia-Pacific’s orthopedic device market medical industry is experiencing an unprecedented boom. From… Read More
The global orthopedic device markett is witnessing transformative growth, fueled by technological advancements, an aging population, and rising demand for… Read More
North America seized 42% of the generative AI in life science market share in 2024. But what fueled this dominance?… Read More
San Diego, CA, July 18, 2025 Acadia Pharmaceuticals, a leader in treatments for neurological and rare diseases, has unveiled an… Read More
Warsaw, IN, July 18, 2025 – Zimmer Biomet Holdings, Inc., a leading innovator in medical technology, has announced a definitive… Read More
London, July 18, 2025 – ViiV Healthcare, a global leader in HIV-focused pharmaceutical innovation, unveiled data from its Phase 3b… Read More